Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating a combination of mosunetuzumab and polatuzumab vedotin with split-dose CHP chemotherapy in elderly patients with diffuse larg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: NOT_YET_RECRUITING